Ever wonder how Oscar Health Q2 2025 earnings compare to its ambitious profitability targets—especially with medical costs rising and risk pools changing rapidly? This quarter’s report is more than just a snapshot of second-quarter results. It’s a roadmap showing how Oscar Health plans to scale revenue, absorb a spike in medical loss ratio, and still stick the landing on its 2026 profitability target.
Let’s break it down—no corporate safe‑harbor monologues, just the numbers and the story they tell.
Oscar Health Q2 2025 Revenue Growth: How They Hit $2.9B
Oscar Health second-quarter results clocked $2.9 billion in revenue, up 29% year over year, according to the official Q2 2025 earnings press release from Oscar Health. That’s a serious growth rate for a player in the ACA individual market, and it didn’t happen by accident. Management points to three levers:
- Membership Growth – More than 2 million members at quarter‑end, up 28% YoY.
- Solid Retention – Fewer lapses and above‑market growth during open enrollment kept the base sticky.
- Special Enrollment Period Adds – Continuous monthly SEPs through mid‑year boosted headcount, even before the fall enrollment push.
For retail investors, the revenue surge sounds great—until you flip the page to the medical loss ratio (MLR).
Oscar Health Q2 2025 Earnings: Key Stats at a Glance
| Metric | Q2 2025 | YoY Change |
|---|---|---|
| Revenue | $2.9 B | +29% |
| Membership | 2.027 M | +28% |
| Medical Loss Ratio (MLR) | 91.1% | +1,200 bps |
| SG&A Expense Ratio | 18.7% | –90 bps |
| Loss from Operations | –$230 M | ▼ $298 M |
| Adjusted EBITDA | –$199 M | ▼ $304 M |
Oscar Health Medical Loss Ratio: Why MLR Jumped to 91.1%
This quarter’s MLR at 91.1% is up 12 points from last year, and the culprit is clear: a $316 million hit to the risk adjustment payable.
CEO Mark Bertolini told investors the morbidity shift—sicker members joining the ACA market—was industry‑wide, fueled by Medicaid redeterminations and the exit of healthier, low‑utilizing members.
“We expect double‑digit rate increases in 2026 to address current morbidity pressure,” Bertolini said. “The market is resilient, and we remain confident in its long‑term growth.”
For a broader market view beyond management’s outlook, see the latest Oscar Health stock forecast and analyst price targets to compare Wall Street’s expectations with the company’s guidance.
Oscar Health SG&A Expenses: Trimming Costs Amid Morbidity Pressure
Even with the MLR headwind, Oscar Health SG&A expense ratio improved to 18.7%, down from 19.6% a year ago. CFO Scott Blackley credited lower exchange fees and fixed‑cost leverage, partially offset by the higher risk adjustment payable as a share of premium.
That efficiency matters because Oscar is rightsizing its workforce in the back half of 2025—expected to cut $60 million in administrative costs starting in 2026.
Why it matters for investors: A leaner cost structure means rate hikes can flow more cleanly to the bottom line when morbidity stabilizes.
Oscar Health 2025 Guidance: Are Profitability Targets Still Intact?
Oscar reaffirmed its 2025 guidance despite the morbidity spike:
- Revenue: $12.0 B – $12.2 B
- Operating Loss: $200 M – $300 M
- Full‑Year MLR: 86% – 87%
- SG&A Ratio: 17.1% – 17.6%
- Adjusted EBITDA Loss: ~$120 M
Management’s takeaway: the market’s in a “reset moment” now, but rate filings and cost discipline set the stage for a return to profitability in 2026.
Revenue vs. Rising Medical Costs
- Revenue up 29% to $2.9 B on membership growth and retention.
- MLR surge to 91.1% driven by $316 M risk adjustment hit.
- SG&A efficiency improving despite morbidity pressure.
- $60 M in cost cuts coming in 2026 from workforce and vendor savings.
- 2025 guidance intact; profitability target holds for 2026.
This video covers the good (29% YoY revenue growth, strong membership gains, lower SG&A ratio), the bad (a spike in medical loss ratio to 91.1%, swinging back to a net loss), and the ugly (double miss on EPS and revenue). Despite the sector-wide headwinds, they remain bullish long term—citing management’s reaffirmed guidance for 2026 profitability and 2027 $14B revenue with 5% margins. They walk through valuation models, showing that even under a conservative bear case, the stock could be undervalued, and they personally plan to hold for the next 2–10 years.
Oscar Health’s Growth Plan: ICRA Expansion and Strategic Bets
Oscar’s strategy leans heavily on expanding its ICRA presence and gaining more control over how consumers discover, choose, and stick with its plans. The moves this quarter suggest a company that isn’t just reacting to the market reset but actively building for a stronger 2026.
Oscar Health + Hy-Vee: ICRA Launch and Brand Leverage
To accelerate its employer‑driven ACA strategy, Oscar partnered with Hy‑Vee, a well‑known Midwest grocery and pharmacy chain. Together, they’ll launch a Hy‑Vee Health‑branded ICRA plan in Des Moines for plan year 2026, pending state approval. By tying its offering to a trusted regional brand, Oscar lowers the barrier for employers and employees to try something new, while adding concierge‑style primary care through Hy‑Vee Health Exemplar Care clinics at a fixed, affordable price.
“Our new ICRA assets will let us meet and exceed expectations of consumers and employers,” CEO Mark Bertolini told analysts. “We’re building the consumer marketplace of the future.”
Hy‑Vee deal takeaways:
- Immediate brand recognition in a new region
- Concierge medicine built into plan design
- Positions Oscar to expand ICRA in future markets
Oscar’s Distribution Play: INSX Cloud and More
This quarter, Oscar also made a trio of acquisitions that pull more of the insurance‑shopping process in‑house. The biggest is INSX Cloud, one of only 11 CMS‑approved direct enrollment platforms. That means Oscar now owns the digital storefront where many customers start their coverage search.
The purchase of IHC Specialty Benefits adds a national brokerage selling both individual and supplemental coverage across carriers, opening cross‑selling opportunities without adding medical risk. And the acquisition of healthinsurance.org, a consumer education site, brings in organic leads from shoppers already in research mode.
By controlling these touchpoints, Oscar captures more of the distribution margin, gains richer customer data, and can use that intelligence to improve retention and targeting.
Oscar Health AI Strategy: Tech-Driven Efficiency and Fraud Control
The other leg of Oscar’s growth engine is efficiency. The company is aiming for $60 million in annual administrative savings starting in 2026, driven by workforce reductions and vendor consolidation. But the plan isn’t just about cutting—it’s also about directing care more intelligently.
Using its AgenTeq AI tools, Oscar is guiding members to the right care at the right time, which helps prevent costly, unnecessary visits. They’re also applying AI to detect fraud, waste, and abuse before it hits the claims ledger. These moves combine back‑office savings with front‑end medical cost control—two levers that matter in a high‑morbidity environment.
Growth Moves and Operating Levers
- Hy‑Vee partnership launches a branded ICRA product with built‑in concierge care in the Midwest.
- Acquisitions of INSX Cloud, IHC Specialty Benefits, and healthinsurance.org pull distribution and marketing in‑house.
- AI tools target $60 million in annual cost savings and better care navigation by 2026.
Oscar Health Q2 2025 Analyst Q&A: Rate Filings, Risk Pools & Long-Term Targets
Earnings calls often get more revealing once the analyst questions start, and Oscar Health Q2 2025 was no exception. The back‑and‑forth shed light on rate filing approvals, risk‑pool stability, and whether management still believes in its 2027 profitability targets despite the 2025 market reset.
Oscar Health 2026 Rate Filings: How State Regulators Are Reacting
Analysts wanted to know if the double‑digit rate hikes Oscar has filed for 2026 would actually get approved. Bertolini’s take was confident: regulators understand the pricing need, and in some markets, they’re urging carriers to price high enough to protect market stability.
That matters because in the ACA world, chasing share with low rates can backfire when claims spike. Oscar’s filings now cover almost all membership and include:
- The full morbidity impact from 2025
- Expected program‑integrity effects
- The possible expiration of enhanced premium tax credits
Oscar Health Risk Adjustment: Is the Worst Behind Us?
CFO Scott Blackley addressed whether the risk pool could worsen in the second half of the year. His answer: most major disruptors are already baked in. The dual‑eligible clean‑up affects just 2.5% of members, and many will likely move back to Medicaid—removing higher utilizers from the pool. SEP growth is slowing, and the Q4 utilization bump (if subsidies lapse) should be offset by tighter claims controls.
“We think the market morbidity shift has already manifested in the first half,” Blackley told analysts. “We’ve pulled the right levers to handle what’s ahead.”
Key risk‑pool takeaways:
- Small dual‑eligible exposure could improve morbidity if higher utilizers leave
- SEP growth is moderating into the back half
- Claims oversight and fraud‑prevention efforts could cushion any late‑year utilization spike
Oscar’s 2027 Targets: EPS and Margin Still on the Table
When asked about the 5% margin and $2.25 EPS targets for 2027, Bertolini didn’t budge. While pricing season and 2026 membership will influence the path, there’s no intention to revise them now.
For investors, that’s a clear signal: Oscar still expects the combination of 2026 repricing, membership retention, and $60 million in administrative savings to create a normal‑looking, profitable insurer with a tech‑driven edge.
Analyst Q&A and Long-Term Outlook
- Regulators appear supportive of Oscar’s double‑digit rate hikes for 2026.
- Risk‑pool deterioration seems contained, with some trends potentially improving morbidity.
- Long‑term 2027 targets remain in play, signaling confidence in the recovery plan.
- Success depends on rate approvals and cost‑saving execution.
Oscar Health Capital and Cash Flow: Can They Fund the 2026 Plan?
After covering growth moves and market stabilization, the next big investor question is simple: Can Oscar afford this plan without coming back to shareholders for cash? The Q2 2025 call made it clear—management believes the answer is yes.
Oscar’s Balance Sheet: Capital Cushion for 2025 Losses
Oscar ended the quarter with $5.4 billion in cash and investments, including $2 billion at the parent level. Insurance subsidiaries hold $1.2 billion in capital and surplus, of which $579 million is excess capital. That cushion matters because it’s where the majority of this year’s projected losses will be absorbed. The parent cash balance will dip in the back half of 2025 due to capital contributions to certain subsidiaries, but management insists levels will remain more than sufficient to cover holding‑company costs.
“We feel really good about where our capital position was going into this change in market morbidity,” CFO Scott Blackley said, “and we’re confident we’ve got the access to funding we need to continue to run this company.”
Funding the Plan: Oscar’s Low-Leverage Strategy
Oscar runs a virtually unlevered balance sheet, which gives it the option to add debt if needed instead of issuing new shares. This flexibility is important in the ACA space, where growth plans can be capital‑intensive but dilution can spook investors. The company also has a revolver set to expire at year‑end, which it is actively working to extend and improve.
Capital strategy takeaways:
- Strong cash and investment position covers near‑term losses
- Excess capital in insurance subsidiaries acts as a buffer
- Low leverage allows borrowing without immediate equity dilution
Oscar Health Cash Flow and Risk Management Outlook
Looking ahead, the path to self‑funded growth hinges on 2026 rate resets, cost savings, and maintaining membership scale. Management expects the revised rate filings to provide enough margin lift to improve cash generation significantly next year. If realized, those gains—combined with the $60 million in SG&A savings—could bring operating cash flow into the black without outside funding.
Oscar also stressed its discipline in capital deployment, noting that recent acquisitions were funded from its existing cash reserves, not debt or new equity. That’s a sign it’s balancing growth investments with liquidity preservation, even as it builds out its ICRA and distribution capabilities.
Cash, Capital, and Flexibility
- $5.4 billion in cash and investments provides a buffer to absorb 2025’s losses.
- Virtually no debt means Oscar can raise capital without issuing shares.
- Extended revolver and careful cash deployment support the 2026 profitability target.
The call features Oscar Health’s management discussing official Q2 2025 results, building on the preliminary numbers. They review membership growth, revenue up nearly 30% YoY, and progress toward cost control with a lower SG&A ratio. They also address the higher medical loss ratio and reaffirm targets for 2026 profitability and 2027 $14B revenue with ~5% margins. The Q&A portion includes analyst questions on pricing, market expansion, and how the company plans to sustain margins in a competitive insurance landscape.
Did Oscar Deliver on Its Q1 2025 Promises?
Oscar Health came into Q2 riding high on a $275 million net income, record-low SG&A, and strong membership growth from Q1. But Q2 told a different story—one shaped by morbidity shocks, risk adjustment spikes, and reset expectations for the rest of the year. So what actually got done? What shifted? Let’s break it down.
Accomplished
Membership Growth and Retention Held Strong
- Q1 Prediction: Membership would trend up in the first half due to SEP momentum and high payment rates, then taper in the second half.
- Q2 Reality: Membership hit 2.027 million, up 28% YoY, confirming the expected growth trajectory and solid retention. SEP adds continued to outperform through mid-year.
SG&A Efficiency Continued (Though with Some Reversion)
- Q1 Highlight: SG&A ratio hit a historic low at 15.8%, and management promised cost discipline would persist—despite some seasonal increases.
- Q2 Result: SG&A ratio increased to 18.7%, as expected. But Oscar reiterated its $60 million in 2026 cost-cutting plans, signaling execution is still on track even as ratios normalize.
Technology Tools Rolled Out
- Q1 Rollout: Oscar launched AI-powered care guides and live chat for Virtual Urgent Care, aiming to boost provider efficiency and member responsiveness.
- Q2 Status: These tools were spotlighted again in Q2, as part of the strategy to reduce administrative burden and support SG&A savings in 2026—confirming continued deployment and integration.
Not Accomplished or Changed
Profitability Took a Hit (But Was Explained)
- Q1 Results: Net income of $275 million and adjusted EBITDA of $329 million made Q1 a historic outlier.
- Q2 Slide: Oscar posted an adjusted EBITDA loss of $199 million and an operating loss of $230 million—a $500 million swing from Q1. The culprit? A $316 million spike in risk adjustment payable, largely tied to a sicker member mix following Medicaid redeterminations.
While this doesn’t invalidate Q1’s progress, it marked a reset moment for the full-year outlook and required major repricing efforts in the 2026 rate filings.
MLR Spiked Sharply
- Q1 MLR: 75.4%, with only a minor impact from risk adjustment ($92 million tied to 2024 true-up).
- Q2 MLR: 91.1%, a 12-point YoY jump. This blew past expectations and forced Oscar to reaffirm its guidance through cost offsets and rate hikes, rather than actual margin expansion in 2025.
No Upward Revision to 2025 Guidance
- Q1 Confidence: Management reaffirmed full-year guidance with optimism and a hint that upside was possible.
- Q2 Reality: Guidance remained unchanged, but the tone shifted to defense. Management framed 2025 as a “reset year,” with 2026 profitability still in sight—but now dependent on execution, repricing, and membership stability.
Why This Matters
The Q1 call promised momentum, and Oscar did follow through on member growth, SG&A discipline, and digital execution. But Q2 revealed just how vulnerable those gains were to risk pool volatility and policy shifts.
This comparison shows the value of tracking back-to-back calls. Retail investors looking at Oscar’s story through just one quarter might miss the context. Q1’s highs and Q2’s hits both matter—because how Oscar handles the back half of the year will determine whether 2026 becomes a real inflection point or just another deferred target.
Want the full backstory behind these numbers?
Check out our Oscar Health Q2 2025 Preliminary Earnings Breakdown for the early data, market context, and what management was signaling before the official results landed.
Health Profitability Path: What Must Go Right for 2026?
With the capital position addressed, the next question is whether Oscar can actually cross the profitability line in 2026—and stay there. Management is confident, but the market wants to see evidence that rate increases, cost savings, and member retention will all land on target.
2026: The Path Back to the Black
Oscar’s updated rate filings are designed to lift margins enough to cover the current morbidity drag. The assumption is that double‑digit premium hikes, combined with a stabilized risk pool, will bring the full‑year medical loss ratio down to the mid‑80s. Layer on the $60 million in administrative cost cuts and improved operating leverage, and both operating income and adjusted EBITDA are expected to turn positive.
“We’ve built in conservative assumptions about program integrity impacts, morbidity, and trend,” Bertolini said. “The plan we’ve filed for 2026 positions us to hit profitability and expand margins from there.”
The Watch List: Known Risks That Could Shift the Timeline
Even with a clear plan, Oscar flagged several potential headwinds that could delay or dilute the 2026 recovery:
- Wage and inflation pressure increasing SG&A beyond expectations
- Higher‑than‑modeled utilization if subsidy changes trigger late‑year care spikes
- Competitive pricing shifts if peers undercut in key markets, risking membership retention
Investor Focus for the Back Half of 2025
For now, the company says the heavy lift—repricing, regulatory approvals, and cost‑cutting—has already been set in motion. The next six months will be about executing on those levers while watching the market response to rate filings. Investors should expect clearer margin guidance once open enrollment closes, giving a better read on membership retention and early 2026 revenue visibility.
If the risk pool remains stable, rate increases stick, and the SG&A savings track to plan, Oscar could enter 2026 with both a leaner cost base and a healthier premium‑to‑claims spread. That’s the kind of setup that can turn a beaten‑down ACA carrier into a cash‑generating business.
Path to 2026 and Red Flags Ahead
- Management expects 2026 to mark the return to profitability, driven by pricing, stable morbidity, and $60 million in cost cuts.
- Key risks: wage inflation, higher utilization, and aggressive competitor pricing.
- Back‑half 2025 execution will set the tone for investor confidence heading into 2026.
This was not just a quarter of explaining away losses. It was a quarter of resetting the market math, shoring up the balance sheet, and laying out the roadmap to 2026 profitability. For a company in the ACA space—where volatility can derail even seasoned carriers—that combination is worth noting.
Oscar Health Recovery Plan: Are All the Pieces in Place?
Management didn’t sugarcoat the impact of the 2025 morbidity spike, but they paired that realism with a tangible plan. Rate filings are in motion, cost‑cutting is underway, and new growth plays—like the Hy‑Vee ICRA launch and the acquisitions of INSX Cloud, IHC Specialty Benefits, and healthinsurance.org—are already being integrated. The message to investors: the pieces needed for a return to the black are already on the board.
“We expect to return to profitability in 2026,” Bertolini reiterated. “We’re focused on what we can control—pricing, cost discipline, and delivering value to our members.”
Oscar Q2 2025 key themes:
- 2025’s headwinds are largely priced into 2026 rates
- Cost discipline now targeting $60 million in annual savings
- Distribution control and ICRA expansion position Oscar for longer‑term growth
Oscar Health Q3 2025 Preview: What Investors Should Track Now
Heading into the back half of 2025, the critical investor checkpoints will be open‑enrollment results, early signals from state regulators on rate approvals, and any shifts in competitor pricing. Watch for management updates on the Hy‑Vee rollout timeline, and keep an ear out for progress reports on AI‑driven efficiency gains—they’ll be a tell for whether those SG&A savings will stick.
For retail investors, Oscar’s path isn’t risk‑free. But if the rate reset holds, the cost base shrinks, and the new distribution funnel starts delivering, the company could move from a “turnaround” label to a “profitable growth” story within the next 18 months.
Want more insights like this?
This site is built for retail investors who want straightforward, in-depth breakdowns of earnings calls—without the jargon. Whether you follow SoFi, Amazon, Dutch Bros, or other high-growth names, we’ve got you covered. Explore our latest posts and stay tuned—new recaps and insights drop regularly.
Check out our dedicated Oscar Health page for all the latest posts and deep‑dives, from earnings breakdowns to fresh analyst takes—bookmark it and never miss a beat.
Written by Bryan Smith, creator of Straight From the Call.
I break down earnings calls so you don’t have to. Clear takeaways, no fluff — just the stuff investors care about.
This post is for informational and educational purposes only. It does not constitute financial, investment, or legal advice. Always do your own research or consult a licensed professional before making financial decisions. For the full policy, see our Not Investment Advice & Disclosure Statement